Health Press Release – Newsletter for December 16, 2010

The First Biotechnology Company That Measures Telomeres

Dr. Mar??a Blasco, the Bot??n Foundation and Matlin Associates Establish Life Length, S.L.

MADRID, December 15, 2010 – Life Length, S.L. is a new biotechnology company set up to
measure the length of telomeres which form caps at the end of chromosomes and
that have a fundamental role in avoiding the break down and the aging of
cells … Read more »»».

Agendia Publishes Compelling First Independent Validation Study of Colon Cancer Recurrence Test “ColoPrint” in Journal of Clinical Oncology

Second Independent Validation Study of ColoPrint Selected for Oral Presentation and Press Conference at ASCO GI in January 2011

IRVINE, California and AMSTERDAM, December 15, 2010 – Agendia, a world leader in molecular cancer diagnostics,
announced today that together with principal investigators from Spain, the
UK, and the Netherlands, it has published the first independent validation
study of …. Original article  : Agendia Publishes Compelling First Independent Validation Study of Colon Cancer Recurrence Test "ColoPrint" in Journal of Clinical Oncology.

Elsevier Bringing Together Thought Leaders and Experts for New International Conference in Bionic Engineering

AMSTERDAM, December 15, 2010 – The International Bionic Engineering Conference 2011 (
www.bionicengineeringconference.com/index.html) organised by Elsevier,
the leading publisher of scientific, technical and medical information
products and services, aims to bridge the gap between academic research and
industrial development in a field that is rapidly growing and gaining
recognition across many disciplines.

Intended as a common …. Source  : Elsevier Bringing Together Thought Leaders and Experts for New International Conference in Bionic Engineering.

Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor

Potential Utility in Various Cancers
SAN DIEGO, December 15, 2010 – Amira Pharmaceuticals, Inc. announced today that it has successfully
identified a novel pre-clinical candidate for its newest lysophosphatidic
acid (LPA)-related program, autotaxin. Autotaxin is an enzyme upstream from
LPA receptors and has been implicated in a number of diseases including
rheumatoid arthritis, glioblastoma, lung, breast, ovarian and thyroid
cancers.

… Read more : Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor.

Valkee Closes Angel Funding With Esther Dyson and Anssi Vanjoki

HELSINKI, December 15, 2010 – Esther Dyson and Anssi Vanjoki have invested in Valkee as part
of company's EUR 400,000 angel round. Valkee makes the bright light headset
to treat and prevent seasonal affective disorder and other depression types.
In clinical trials, 9 out of 10 patients have had symptoms relief in four
weeks, using Valkee 8-12 minutes …. Original article on Gaea Times at  : Valkee Closes Angel Funding With Esther Dyson and Anssi Vanjoki.